高性能医薬品有効成分（HPAPI）の世界市場（～2026年）

• 英文タイトル：Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Insights and Forecast to 2026

• レポートコード：MRC2-11QY01193 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,170,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料は高性能医薬品有効成分（HPAPI）のグローバル市場について調査・分析したレポートです。種類別（合成成分、生物成分、その他）市場規模、用途別（腫瘍学、緑内障、抗糖尿病、心臓血管、筋骨格、ホルモン、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別高性能医薬品有効成分（HPAPI）の競争状況、市場シェア ・世界の高性能医薬品有効成分（HPAPI）市場：種類別市場規模 2015年-2020年（合成成分、生物成分、その他） ・世界の高性能医薬品有効成分（HPAPI）市場：種類別市場規模予測 2021年-2026年（合成成分、生物成分、その他） ・世界の高性能医薬品有効成分（HPAPI）市場：用途別市場規模 2015年-2020年（腫瘍学、緑内障、抗糖尿病、心臓血管、筋骨格、ホルモン、その他） ・世界の高性能医薬品有効成分（HPAPI）市場：用途別市場規模予測 2021年-2026年（腫瘍学、緑内障、抗糖尿病、心臓血管、筋骨格、ホルモン、その他） ・北米の高性能医薬品有効成分（HPAPI）市場分析：米国、カナダ ・ヨーロッパの高性能医薬品有効成分（HPAPI）市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの高性能医薬品有効成分（HPAPI）市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の高性能医薬品有効成分（HPAPI）市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの高性能医薬品有効成分（HPAPI）市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Bristol-Myers Squibb、Novartis、Sanofi Aventis、Pfizer、Lonza、Novasep、Hospira、BASF、Merck、Bayer、Teva Pharmaceuticals、Boehringer Ingelheim ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論

Market Analysis and Insights: Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market
The global High Performance Active Pharmaceutical Ingredients (HPAPI) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global High Performance Active Pharmaceutical Ingredients (HPAPI) Scope and Market Size
High Performance Active Pharmaceutical Ingredients (HPAPI) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global High Performance Active Pharmaceutical Ingredients (HPAPI) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the High Performance Active Pharmaceutical Ingredients (HPAPI) market is segmented into
Synthetic Ingredients
Biological Ingredients
Others

Segment by Application, the High Performance Active Pharmaceutical Ingredients (HPAPI) market is segmented into
Oncology
Glaucoma
Anti-diabetic
Cardiovascular
Musculoskeletal
Hormonal
Others

Regional and Country-level Analysis
The High Performance Active Pharmaceutical Ingredients (HPAPI) market is analysed and market size information is provided by regions (countries).
The key regions covered in the High Performance Active Pharmaceutical Ingredients (HPAPI) market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and High Performance Active Pharmaceutical Ingredients (HPAPI) Market Share Analysis
High Performance Active Pharmaceutical Ingredients (HPAPI) market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in High Performance Active Pharmaceutical Ingredients (HPAPI) business, the date to enter into the High Performance Active Pharmaceutical Ingredients (HPAPI) market, High Performance Active Pharmaceutical Ingredients (HPAPI) product introduction, recent developments, etc.

The major vendors covered:
Bristol-Myers Squibb
Novartis
Sanofi Aventis
Pfizer
Lonza
Novasep
Hospira
BASF
Merck
Bayer
Teva Pharmaceuticals
Boehringer Ingelheim

レポート目次

---

1 Study Coverage
1.1 High Performance Active Pharmaceutical Ingredients (HPAPI) Product Introduction
1.2 Market Segments
1.3 Key High Performance Active Pharmaceutical Ingredients (HPAPI) Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Growth Rate by Type
1.4.2 Synthetic Ingredients
1.4.3 Biological Ingredients
1.4.4 Others
1.5 Market by Application
1.5.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Growth Rate by Application
1.5.2 Oncology
1.5.3 Glaucoma
1.5.4 Anti-diabetic
1.5.5 Cardiovascular
1.5.6 Musculoskeletal
1.5.7 Hormonal
1.5.8 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size, Estimates and Forecasts
2.1.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue 2015-2026
2.1.2 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales 2015-2026
2.2 Global High Performance Active Pharmaceutical Ingredients (HPAPI), Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Competitor Landscape by Players
3.1 High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Manufacturers
3.1.1 High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Manufacturers (2015-2020)
3.1.2 High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Manufacturers (2015-2020)
3.2 High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue by Manufacturers
3.2.1 High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue by Manufacturers (2015-2020)
3.2.2 High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Share by Manufacturers (2015-2020)
3.2.3 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue in 2019
3.2.5 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 High Performance Active Pharmaceutical Ingredients (HPAPI) Price by Manufacturers
3.4 High Performance Active Pharmaceutical Ingredients (HPAPI) Manufacturing Base Distribution, Product Types
3.4.1 High Performance Active Pharmaceutical Ingredients (HPAPI) Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers High Performance Active Pharmaceutical Ingredients (HPAPI) Product Type
3.4.3 Date of International Manufacturers Enter into High Performance Active Pharmaceutical Ingredients (HPAPI) Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size by Type (2015-2020)
4.1.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Type (2015-2020)
4.1.2 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue by Type (2015-2020)
4.1.3 High Performance Active Pharmaceutical Ingredients (HPAPI) Average Selling Price (ASP) by Type (2015-2026)
4.2 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Forecast by Type (2021-2026)
4.2.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Forecast by Type (2021-2026)
4.2.2 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Forecast by Type (2021-2026)
4.2.3 High Performance Active Pharmaceutical Ingredients (HPAPI) Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size by Application (2015-2020)
5.1.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Application (2015-2020)
5.1.2 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue by Application (2015-2020)
5.1.3 High Performance Active Pharmaceutical Ingredients (HPAPI) Price by Application (2015-2020)
5.2 High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Forecast by Application (2021-2026)
5.2.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Forecast by Application (2021-2026)
5.2.2 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Forecast by Application (2021-2026)
5.2.3 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Price Forecast by Application (2021-2026)

6 North America
6.1 North America High Performance Active Pharmaceutical Ingredients (HPAPI) by Country
6.1.1 North America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Country
6.1.2 North America High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America High Performance Active Pharmaceutical Ingredients (HPAPI) Market Facts & Figures by Type
6.3 North America High Performance Active Pharmaceutical Ingredients (HPAPI) Market Facts & Figures by Application

7 Europe
7.1 Europe High Performance Active Pharmaceutical Ingredients (HPAPI) by Country
7.1.1 Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Country
7.1.2 Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Market Facts & Figures by Type
7.3 Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) by Region
8.1.1 Asia Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Region
8.1.2 Asia Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Market Facts & Figures by Type
8.3 Asia Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Market Facts & Figures by Application

9 Latin America
9.1 Latin America High Performance Active Pharmaceutical Ingredients (HPAPI) by Country
9.1.1 Latin America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Country
9.1.2 Latin America High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America High Performance Active Pharmaceutical Ingredients (HPAPI) Market Facts & Figures by Type
9.3 Central & South America High Performance Active Pharmaceutical Ingredients (HPAPI) Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) by Country
10.1.1 Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Country
10.1.2 Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Market Facts & Figures by Type
10.3 Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Market Facts & Figures by Application

11 Company Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Corporation Information
11.1.2 Bristol-Myers Squibb Description and Business Overview
11.1.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Bristol-Myers Squibb High Performance Active Pharmaceutical Ingredients (HPAPI) Products Offered
11.1.5 Bristol-Myers Squibb Related Developments
11.2 Novartis
11.2.1 Novartis Corporation Information
11.2.2 Novartis Description and Business Overview
11.2.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Novartis High Performance Active Pharmaceutical Ingredients (HPAPI) Products Offered
11.2.5 Novartis Related Developments
11.3 Sanofi Aventis
11.3.1 Sanofi Aventis Corporation Information
11.3.2 Sanofi Aventis Description and Business Overview
11.3.3 Sanofi Aventis Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Sanofi Aventis High Performance Active Pharmaceutical Ingredients (HPAPI) Products Offered
11.3.5 Sanofi Aventis Related Developments
11.4 Pfizer
11.4.1 Pfizer Corporation Information
11.4.2 Pfizer Description and Business Overview
11.4.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Pfizer High Performance Active Pharmaceutical Ingredients (HPAPI) Products Offered
11.4.5 Pfizer Related Developments
11.5 Lonza
11.5.1 Lonza Corporation Information
11.5.2 Lonza Description and Business Overview
11.5.3 Lonza Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Lonza High Performance Active Pharmaceutical Ingredients (HPAPI) Products Offered
11.5.5 Lonza Related Developments
11.6 Novasep
11.6.1 Novasep Corporation Information
11.6.2 Novasep Description and Business Overview
11.6.3 Novasep Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Novasep High Performance Active Pharmaceutical Ingredients (HPAPI) Products Offered
11.6.5 Novasep Related Developments
11.7 Hospira
11.7.1 Hospira Corporation Information
11.7.2 Hospira Description and Business Overview
11.7.3 Hospira Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Hospira High Performance Active Pharmaceutical Ingredients (HPAPI) Products Offered
11.7.5 Hospira Related Developments
11.8 BASF
11.8.1 BASF Corporation Information
11.8.2 BASF Description and Business Overview
11.8.3 BASF Sales, Revenue and Gross Margin (2015-2020)
11.8.4 BASF High Performance Active Pharmaceutical Ingredients (HPAPI) Products Offered
11.8.5 BASF Related Developments
11.9 Merck
11.9.1 Merck Corporation Information
11.9.2 Merck Description and Business Overview
11.9.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Merck High Performance Active Pharmaceutical Ingredients (HPAPI) Products Offered
11.9.5 Merck Related Developments
11.10 Bayer
11.10.1 Bayer Corporation Information
11.10.2 Bayer Description and Business Overview
11.10.3 Bayer Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Bayer High Performance Active Pharmaceutical Ingredients (HPAPI) Products Offered
11.10.5 Bayer Related Developments
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Corporation Information
11.1.2 Bristol-Myers Squibb Description and Business Overview
11.1.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Bristol-Myers Squibb High Performance Active Pharmaceutical Ingredients (HPAPI) Products Offered
11.1.5 Bristol-Myers Squibb Related Developments
11.12 Boehringer Ingelheim
11.12.1 Boehringer Ingelheim Corporation Information
11.12.2 Boehringer Ingelheim Description and Business Overview
11.12.3 Boehringer Ingelheim Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Boehringer Ingelheim Products Offered
11.12.5 Boehringer Ingelheim Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 High Performance Active Pharmaceutical Ingredients (HPAPI) Market Estimates and Projections by Region
12.1.1 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Forecast by Regions 2021-2026
12.1.2 Global High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Forecast by Regions 2021-2026
12.2 North America High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Forecast (2021-2026)
12.2.1 North America: High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Forecast (2021-2026)
12.2.2 North America: High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Forecast (2021-2026)
12.2.3 North America: High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Forecast by Country (2021-2026)
12.3 Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Forecast (2021-2026)
12.3.1 Europe: High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Forecast (2021-2026)
12.3.2 Europe: High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Forecast (2021-2026)
12.3.3 Europe: High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Forecast (2021-2026)
12.4.2 Asia Pacific: High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Forecast by Region (2021-2026)
12.5 Latin America High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Forecast (2021-2026)
12.5.1 Latin America: High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Forecast (2021-2026)
12.5.2 Latin America: High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Forecast (2021-2026)
12.5.3 Latin America: High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key High Performance Active Pharmaceutical Ingredients (HPAPI) Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 High Performance Active Pharmaceutical Ingredients (HPAPI) Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

List of Tables
Table 1. High Performance Active Pharmaceutical Ingredients (HPAPI) Market Segments
Table 2. Ranking of Global Top High Performance Active Pharmaceutical Ingredients (HPAPI) Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Growth Rate by Type 2020-2026 (K MT) & (US$ Million)
Table 4. Major Manufacturers of Synthetic Ingredients
Table 5. Major Manufacturers of Biological Ingredients
Table 6. Major Manufacturers of Others
Table 7. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Growth Rate by Application 2020-2026 (K MT)
Table 8. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size by Region (K MT) & (US$ Million): 2020 VS 2026
Table 9. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Regions 2015-2020 (K MT)
Table 10. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Regions (2015-2020)
Table 11. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue by Regions 2015-2020 (US$ Million)
Table 12. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Manufacturers (2015-2020) (K MT)
Table 13. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Share by Manufacturers (2015-2020)
Table 14. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 15. Global High Performance Active Pharmaceutical Ingredients (HPAPI) by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in High Performance Active Pharmaceutical Ingredients (HPAPI) as of 2019)
Table 16. High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue by Manufacturers (2015-2020) (US$ Million)
Table 17. High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Share by Manufacturers (2015-2020)
Table 18. Key Manufacturers High Performance Active Pharmaceutical Ingredients (HPAPI) Price (2015-2020) (USD/MT)
Table 19. High Performance Active Pharmaceutical Ingredients (HPAPI) Manufacturers Manufacturing Base Distribution and Headquarters
Table 20. Manufacturers High Performance Active Pharmaceutical Ingredients (HPAPI) Product Type
Table 21. Date of International Manufacturers Enter into High Performance Active Pharmaceutical Ingredients (HPAPI) Market
Table 22. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 23. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Type (2015-2020) (K MT)
Table 24. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Share by Type (2015-2020)
Table 25. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue by Type (2015-2020) (US$ Million)
Table 26. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Share by Type (2015-2020)
Table 27. High Performance Active Pharmaceutical Ingredients (HPAPI) Average Selling Price (ASP) by Type 2015-2020 (USD/MT)
Table 28. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Application (2015-2020) (K MT)
Table 29. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Share by Application (2015-2020)
Table 30. North America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Country (2015-2020) (K MT)
Table 31. North America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Country (2015-2020)
Table 32. North America High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue by Country (2015-2020) (US$ Million)
Table 33. North America High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share by Country (2015-2020)
Table 34. North America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Type (2015-2020) (K MT)
Table 35. North America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Type (2015-2020)
Table 36. North America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Application (2015-2020) (K MT)
Table 37. North America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Application (2015-2020)
Table 38. Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Country (2015-2020) (K MT)
Table 39. Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Country (2015-2020)
Table 40. Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue by Country (2015-2020) (US$ Million)
Table 41. Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share by Country (2015-2020)
Table 42. Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Type (2015-2020) (K MT)
Table 43. Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Type (2015-2020)
Table 44. Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Application (2015-2020) (K MT)
Table 45. Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Application (2015-2020)
Table 46. Asia Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Region (2015-2020) (K MT)
Table 47. Asia Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Region (2015-2020)
Table 48. Asia Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue by Region (2015-2020) (US$ Million)
Table 49. Asia Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share by Region (2015-2020)
Table 50. Asia Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Type (2015-2020) (K MT)
Table 51. Asia Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Type (2015-2020)
Table 52. Asia Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Application (2015-2020) (K MT)
Table 53. Asia Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Application (2015-2020)
Table 54. Latin America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Country (2015-2020) (K MT)
Table 55. Latin America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Country (2015-2020)
Table 56. Latin Americaa High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue by Country (2015-2020) (US$ Million)
Table 57. Latin America High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share by Country (2015-2020)
Table 58. Latin America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Type (2015-2020) (K MT)
Table 59. Latin America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Type (2015-2020)
Table 60. Latin America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Application (2015-2020) (K MT)
Table 61. Latin America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Application (2015-2020)
Table 62. Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Country (2015-2020) (K MT)
Table 63. Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Country (2015-2020)
Table 64. Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue by Country (2015-2020) (US$ Million)
Table 65. Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share by Country (2015-2020)
Table 66. Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Type (2015-2020) (K MT)
Table 67. Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Type (2015-2020)
Table 68. Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Sales by Application (2015-2020) (K MT)
Table 69. Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Application (2015-2020)
Table 70. Bristol-Myers Squibb Corporation Information
Table 71. Bristol-Myers Squibb Description and Major Businesses
Table 72. Bristol-Myers Squibb High Performance Active Pharmaceutical Ingredients (HPAPI) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 73. Bristol-Myers Squibb Product
Table 74. Bristol-Myers Squibb Recent Development
Table 75. Novartis Corporation Information
Table 76. Novartis Description and Major Businesses
Table 77. Novartis High Performance Active Pharmaceutical Ingredients (HPAPI) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 78. Novartis Product
Table 79. Novartis Recent Development
Table 80. Sanofi Aventis Corporation Information
Table 81. Sanofi Aventis Description and Major Businesses
Table 82. Sanofi Aventis High Performance Active Pharmaceutical Ingredients (HPAPI) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 83. Sanofi Aventis Product
Table 84. Sanofi Aventis Recent Development
Table 85. Pfizer Corporation Information
Table 86. Pfizer Description and Major Businesses
Table 87. Pfizer High Performance Active Pharmaceutical Ingredients (HPAPI) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 88. Pfizer Product
Table 89. Pfizer Recent Development
Table 90. Lonza Corporation Information
Table 91. Lonza Description and Major Businesses
Table 92. Lonza High Performance Active Pharmaceutical Ingredients (HPAPI) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 93. Lonza Product
Table 94. Lonza Recent Development
Table 95. Novasep Corporation Information
Table 96. Novasep Description and Major Businesses
Table 97. Novasep High Performance Active Pharmaceutical Ingredients (HPAPI) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 98. Novasep Product
Table 99. Novasep Recent Development
Table 100. Hospira Corporation Information
Table 101. Hospira Description and Major Businesses
Table 102. Hospira High Performance Active Pharmaceutical Ingredients (HPAPI) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 103. Hospira Product
Table 104. Hospira Recent Development
Table 105. BASF Corporation Information
Table 106. BASF Description and Major Businesses
Table 107. BASF High Performance Active Pharmaceutical Ingredients (HPAPI) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 108. BASF Product
Table 109. BASF Recent Development
Table 110. Merck Corporation Information
Table 111. Merck Description and Major Businesses
Table 112. Merck High Performance Active Pharmaceutical Ingredients (HPAPI) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 113. Merck Product
Table 114. Merck Recent Development
Table 115. Bayer Corporation Information
Table 116. Bayer Description and Major Businesses
Table 117. Bayer High Performance Active Pharmaceutical Ingredients (HPAPI) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 118. Bayer Product
Table 119. Bayer Recent Development
Table 120. Teva Pharmaceuticals Corporation Information
Table 121. Teva Pharmaceuticals Description and Major Businesses
Table 122. Teva Pharmaceuticals High Performance Active Pharmaceutical Ingredients (HPAPI) Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 123. Teva Pharmaceuticals Product
Table 124. Teva Pharmaceuticals Recent Development
Table 125. Boehringer Ingelheim Corporation Information
Table 126. Boehringer Ingelheim Description and Major Businesses
Table 127. Boehringer Ingelheim High Performance Active Pharmaceutical Ingredients (HPAPI) Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2015-2020)
Table 128. Boehringer Ingelheim Product
Table 129. Boehringer Ingelheim Recent Development
Table 130. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Forecast by Regions (2021-2026) (K MT)
Table 131. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share Forecast by Regions (2021-2026)
Table 132. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 133. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share Forecast by Regions (2021-2026)
Table 134. North America: High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Forecast by Country (2021-2026) (K MT)
Table 135. North America: High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Forecast by Country (2021-2026) (US$ Million)
Table 136. Europe: High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Forecast by Country (2021-2026) (K MT)
Table 137. Europe: High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Forecast by Country (2021-2026) (US$ Million)
Table 138. Asia Pacific: High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Forecast by Region (2021-2026) (K MT)
Table 139. Asia Pacific: High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Forecast by Region (2021-2026) (US$ Million)
Table 140. Latin America: High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Forecast by Country (2021-2026) (K MT)
Table 141. Latin America: High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Forecast by Country (2021-2026) (US$ Million)
Table 142. Middle East and Africa: High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Forecast by Country (2021-2026) (K MT)
Table 143. Middle East and Africa: High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Forecast by Country (2021-2026) (US$ Million)
Table 144. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 145. Key Challenges
Table 146. Market Risks
Table 147. Main Points Interviewed from Key High Performance Active Pharmaceutical Ingredients (HPAPI) Players
Table 148. High Performance Active Pharmaceutical Ingredients (HPAPI) Customers List
Table 149. High Performance Active Pharmaceutical Ingredients (HPAPI) Distributors List
Table 150. Research Programs/Design for This Report
Table 151. Key Data Information from Secondary Sources
Table 152. Key Data Information from Primary Sources
List of Figures
Figure 1. High Performance Active Pharmaceutical Ingredients (HPAPI) Product Picture
Figure 2. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Type in 2020 & 2026
Figure 3. Synthetic Ingredients Product Picture
Figure 4. Biological Ingredients Product Picture
Figure 5. Others Product Picture
Figure 6. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Application in 2020 & 2026
Figure 7. Oncology
Figure 8. Glaucoma
Figure 9. Anti-diabetic
Figure 10. Cardiovascular
Figure 11. Musculoskeletal
Figure 12. Hormonal
Figure 13. Others
Figure 14. High Performance Active Pharmaceutical Ingredients (HPAPI) Report Years Considered
Figure 15. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size 2015-2026 (US$ Million)
Figure 16. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales 2015-2026 (K MT)
Figure 17. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Size Market Share by Region: 2020 Versus 2026
Figure 18. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Region (2015-2020)
Figure 19. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Region in 2019
Figure 20. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share by Region (2015-2020)
Figure 21. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share by Region in 2019
Figure 22. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Share by Manufacturer in 2019
Figure 23. The Top 10 and 5 Players Market Share by High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue in 2019
Figure 24. High Performance Active Pharmaceutical Ingredients (HPAPI) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 25. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Type (2015-2020)
Figure 26. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Type in 2019
Figure 27. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share by Type (2015-2020)
Figure 28. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share by Type in 2019
Figure 29. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Market Share by Price Range (2015-2020)
Figure 30. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Application (2015-2020)
Figure 31. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Application in 2019
Figure 32. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share by Application (2015-2020)
Figure 33. Global High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share by Application in 2019
Figure 34. North America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate 2015-2020 (K MT)
Figure 35. North America High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 36. North America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Country in 2019
Figure 37. North America High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share by Country in 2019
Figure 38. U.S. High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate (2015-2020) (K MT)
Figure 39. U.S. High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 40. Canada High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate (2015-2020) (K MT)
Figure 41. Canada High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 42. North America High Performance Active Pharmaceutical Ingredients (HPAPI) Market Share by Type in 2019
Figure 43. North America High Performance Active Pharmaceutical Ingredients (HPAPI) Market Share by Application in 2019
Figure 44. Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate 2015-2020 (K MT)
Figure 45. Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 46. Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Country in 2019
Figure 47. Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share by Country in 2019
Figure 48. Germany High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate (2015-2020) (K MT)
Figure 49. Germany High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. France High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate (2015-2020) (K MT)
Figure 51. France High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. U.K. High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate (2015-2020) (K MT)
Figure 53. U.K. High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Italy High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate (2015-2020) (K MT)
Figure 55. Italy High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Russia High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate (2015-2020) (K MT)
Figure 57. Russia High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 58. Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Market Share by Type in 2019
Figure 59. Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Market Share by Application in 2019
Figure 60. Asia Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate 2015-2020 (K MT)
Figure 61. Asia Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 62. Asia Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Region in 2019
Figure 63. Asia Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share by Region in 2019
Figure 64. China High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate (2015-2020) (K MT)
Figure 65. China High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. Japan High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate (2015-2020) (K MT)
Figure 67. Japan High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. South Korea High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate (2015-2020) (K MT)
Figure 69. South Korea High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. India High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate (2015-2020) (K MT)
Figure 71. India High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Australia High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate (2015-2020) (K MT)
Figure 73. Australia High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Taiwan High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate (2015-2020) (K MT)
Figure 75. Taiwan High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Indonesia High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate (2015-2020) (K MT)
Figure 77. Indonesia High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Thailand High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate (2015-2020) (K MT)
Figure 79. Thailand High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Malaysia High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate (2015-2020) (K MT)
Figure 81. Malaysia High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Philippines High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate (2015-2020) (K MT)
Figure 83. Philippines High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Vietnam High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate (2015-2020) (K MT)
Figure 85. Vietnam High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 86. Asia Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Market Share by Type in 2019
Figure 87. Asia Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Market Share by Application in 2019
Figure 88. Latin America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate 2015-2020 (K MT)
Figure 89. Latin America High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 90. Latin America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Country in 2019
Figure 91. Latin America High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share by Country in 2019
Figure 92. Mexico High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate (2015-2020) (K MT)
Figure 93. Mexico High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Brazil High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate (2015-2020) (K MT)
Figure 95. Brazil High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Argentina High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate (2015-2020) (K MT)
Figure 97. Argentina High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 98. Latin America High Performance Active Pharmaceutical Ingredients (HPAPI) Market Share by Type in 2019
Figure 99. Latin America High Performance Active Pharmaceutical Ingredients (HPAPI) Market Share by Application in 2019
Figure 100. Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate 2015-2020 (K MT)
Figure 101. Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate 2015-2020 (US$ Million)
Figure 102. Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Country in 2019
Figure 103. Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share by Country in 2019
Figure 104. Turkey High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate (2015-2020) (K MT)
Figure 105. Turkey High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. Saudi Arabia High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate (2015-2020) (K MT)
Figure 107. Saudi Arabia High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. U.A.E High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate (2015-2020) (K MT)
Figure 109. U.A.E High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate (2015-2020) (US$ Million)
Figure 110. Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Market Share by Type in 2019
Figure 111. Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Market Share by Application in 2019
Figure 112. North America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 113. North America High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 114. Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 115. Europe High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 116. Asia Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 117. Asia Pacific High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 118. Latin America High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 119. Latin America High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 120. Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Sales Growth Rate Forecast (2021-2026) (K MT)
Figure 121. Middle East and Africa High Performance Active Pharmaceutical Ingredients (HPAPI) Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 122. Porter's Five Forces Analysis
Figure 123. Channels of Distribution
Figure 124. Distributors Profiles
Figure 125. Bottom-up and Top-down Approaches for This Report
Figure 126. Data Triangulation
Figure 127. Key Executives Interviewed

---